T3
3,5,3'TRIIODOTHYRONINE
Created: | 1999-07-12 |
Last modified: | 2024-09-27 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 35 |
Chiral Atom Count | 1 |
Bond Count | 36 |
Aromatic Bond Count | 12 |
Chemical Component Summary | |
---|---|
Name | 3,5,3'TRIIODOTHYRONINE |
Synonyms | T3; THYROID HORMONE; LIOTHYRONINE |
Systematic Name (OpenEye OEToolkits) | (2S)-2-amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]propanoic acid |
Formula | C15 H12 I3 N O4 |
Molecular Weight | 650.973 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C(O)C(N)Cc2cc(I)c(Oc1cc(I)c(O)cc1)c(I)c2 |
SMILES | CACTVS | 3.341 | N[CH](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O |
SMILES | OpenEye OEToolkits | 1.5.0 | c1cc(c(cc1Oc2c(cc(cc2I)CC(C(=O)O)N)I)I)O |
Canonical SMILES | CACTVS | 3.341 | N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | c1cc(c(cc1Oc2c(cc(cc2I)C[C@@H](C(=O)O)N)I)I)O |
InChI | InChI | 1.03 | InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1 |
InChIKey | InChI | 1.03 | AUYYCJSJGJYCDS-LBPRGKRZSA-N |
Drug Info: DrugBank
DrugBank ID | DB00279 |
---|---|
Name | Liothyronine |
Groups |
|
Description | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine.[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578] |
Synonyms |
|
Brand Names |
|
Indication | Liothyronine is officially approved for the following indications: - Replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. - As an adjunct therapy to surgery and radioiodine in the management of thyroid cancer. - As a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy.[FDA label] In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.[T457] The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.[T457] Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.[FDA label] |
Categories |
|
ATC-Code |
|
CAS number | 6893-02-3 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Thyroid hormone receptor alpha | MEQKPSKVECGSDPEENSARSPDGKRKRKNGQCSLKTSMSGYIPSYLDKD... | unknown | agonist |
Thyroid hormone receptor beta | MTPNSMTENGLTAWDKPKHCPDREHDWKLVGMSEACLHRKSHSERRSTLK... | unknown | agonist |
Proliferating cell nuclear antigen | MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQL... | unknown | antagonist |
UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL... | unknown | substrate |
Transthyretin | MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAV... | unknown | |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1544 |
PubChem | 5920, 7048703 |
ChEMBL | CHEMBL1544 |
ChEBI | CHEBI:18258, CHEBI:533015 |
CCDC/CSD | LOJLUT |